

Haematologica
HAEMATOL/2017/175380
Version 4

Survival adjusting for crossover: phase 3 study of ibrutinib vs
chlorambucil in older patients with untreated chronic lymphocytic
leukemia/small lymphocytic lymphoma

Steven Coutre, Alessandra Tedeschi, Tadeusz Robak, Paul M. Barr,
Carolyn Owen, Osnat Bairey, Jan Burger, Cathy Zhou, Lori Styles,
Danelle F. James, and Thomas J. Kipps

Disclosures: This manuscript was developed with editorial support from Stacey Rose, PhD, and funded by Pharmacyclics LLC, an AbbVie Company. SC: consultancy/advisory role for AbbVie, Gilead, Novartis, Celgene, Janssen and Pharmacyclics; research funding from AbbVie, Pharmacyclics, Gilead, Celgene, and Novartis. AT: consultancy/advisory role for Janssen, Gilead, and AbbVie; travel expenses from Janssen SPA and Gilead. TR: consultancy/advisory role, honoraria, and research funding from Janssen, Pharmacyclics, and AbbVie. PMB: consultancy/advisory role for Pharmacyclics, AbbVie, Celgene, Novartis, Seattle Genetics, and Infinity; research funding from Pharmacyclics. CO: honoraria from Roche, Lundbeck, Gilead, Janssen, AbbVie, Celgene, and AstraZeneca; consultancy/advisory role for Roche; research funding from Gilead, Pharmacyclics, and Roche. OB: consultancy/advisory role for and research funding from Janssen. JB: consultancy/advisory role, honoraria, and travel expenses from Gilead, TG Therapeutics, Pharmacyclics, Novartis, and Janssen; research funding from Pharmacyclics. CZ, LS, and DFJ: employed by Pharmacyclics LLC, an AbbVie Company and have stock ownership of AbbVie. TJK: consultancy/advisory role for AbbVie, Genentech, Gilead, and Pharmacyclics; research funding from AbbVie, Genentech, Pharmacyclics, and Oncternal.

Contributions: SC, AT, TR, PMB, CO, OB, JB, and TJK collected data, and contributed to the analysis and interpretation of data. CZ, LS, and DFJ contributed to study design, analysis, and interpretation of data. All authors participated in manuscript writing and provided approval of the final version.